<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04274829</url>
  </required_header>
  <id_info>
    <org_study_id>MICRO-PTC-LN</org_study_id>
    <nct_id>NCT04274829</nct_id>
  </id_info>
  <brief_title>Predictive Factors of Lymph Node Metastasis in Patients With Papillary Microcarcinoma of the Thyroid</brief_title>
  <official_title>Predictive Factors of Lymph Node Metastasis in Patients With Papillary Microcarcinoma of the Thyroid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cagliari</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cagliari</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Papillary thyroid microcarcinoma (PTMC), defined as a tumor with larger diameter â‰¤ 1 cm, is
      considered a tumor with an indolent course and an excellent prognosis. Nevertheless, the
      incidence of lymph node metastasis in PTMC is not negligible, reaching up to 65% in some
      series. The aim of this study was to assess the incidence of lymph node metastasis in
      patients with PTMC and to evaluate predictive factors for lymph node metastasis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2010</start_date>
  <completion_date type="Actual">February 2020</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of lymph node metastasis</measure>
    <time_frame>1 year</time_frame>
    <description>To define the incidence of lymph node metastasis in patients with papillary microcarcinoma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Predicrive factors of lymph node metastasis</measure>
    <time_frame>1 year</time_frame>
    <description>To assesss predictive factors of lymph node metastasis</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">300</enrollment>
  <condition>Thyroid Cancer</condition>
  <condition>Lymph Node Metastases</condition>
  <arm_group>
    <arm_group_label>PTMC</arm_group_label>
    <description>Patients with papillary microcarcinoma of the thyroid</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Thyroidecomt and lymphectomy</intervention_name>
    <description>Patients underwent total thyroidectomy or lobectomy associated to lymph node sampling or neck lymphectomy</description>
    <arm_group_label>PTMC</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with papillary thyroid carcinoma
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with papillary microcarcinoma of the thyroid

        Exclusion Criteria:

        Patients with thyroid nodules &gt; 1 cm; incomplete data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AOU Cagliari</name>
      <address>
        <city>Cagliari</city>
        <state>CA</state>
        <zip>09100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 15, 2020</study_first_submitted>
  <study_first_submitted_qc>February 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2020</study_first_posted>
  <last_update_submitted>February 15, 2020</last_update_submitted>
  <last_update_submitted_qc>February 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cagliari</investigator_affiliation>
    <investigator_full_name>Fabio Medas</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

